{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:09:21Z","timestamp":1788307761925,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pcl.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T13:05:51Z","timestamp":1710248751000},"page":"529-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vaccine Development"],"prefix":"10.1016","volume":"71","author":[{"given":"Elizabeth A.D.","family":"Hammershaimb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-040717","article-title":"Enrolling Minors in COVID-19 Vaccine Trials","volume":"147","author":"Mintz","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2024.01.018_bib4","series-title":"Addressing the barriers to pediatric drug development: workshop summary","article-title":"Forum on Drug Discovery D. Regulatory Framework","year":"2008"},{"issue":"17","key":"10.1016\/j.pcl.2024.01.018_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMp2210173","article-title":"What Covid Has Taught the World about Ethics","volume":"387","author":"Emanuel","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1057\/s41271-022-00338-w","article-title":"Ethical allocation of COVID-19 vaccine in the United States: an evaluation of competing frameworks for the current pandemic and future events","volume":"43","author":"Lawrence","year":"2022","journal-title":"J\u00a0Publ Health Pol"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00006454-199902000-00002","article-title":"Smallpox: a history of its rise and fall","volume":"18","author":"Radetsky","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"9401","key":"10.1016\/j.pcl.2024.01.018_bib9","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(03)15111-2","article-title":"Benjamin Jesty: new light in the dawn of vaccination","volume":"362","author":"Pead","year":"2003","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.pcl.2024.01.018_bib11","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1016\/j.vaccine.2020.05.037","article-title":"Early smallpox vaccine manufacturing in the United States: Introduction of the \u201canimal vaccine\u201d in 1870, establishment of \u201cvaccine farms\u201d, and the beginnings of the vaccine industry","volume":"38","author":"Esparza","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.pcl.2024.01.018_bib12","article-title":"ACAM2000 (Smallpox Vaccine) Questions and Answers","year":"2022","journal-title":"FDA"},{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM196701192760301","article-title":"Complications of smallpox vaccination. I. National survey in the United States, 1963","volume":"276","author":"Neff","year":"1967","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2024.01.018_bib14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1542\/peds.42.6.986","article-title":"smallpox vaccination: before or after one year of age?","volume":"42","author":"Neff","year":"1968","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib16","first-page":"E115","article-title":"History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis","year":"2016","journal-title":"J\u00a0Prev Med Hyg"},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/515616","article-title":"Pandemic versus epidemic influenza mortality: a pattern of changing age distribution","volume":"178","author":"Simonsen","year":"1998","journal-title":"J\u00a0Infect Dis"},{"issue":"75","key":"10.1016\/j.pcl.2024.01.018_bib18","first-page":"944","article-title":"Surgeon General. Surgeon General\u2019s Advisory Committee on Influenza Research Report of February, 1960","year":"1960","journal-title":"Publ Health Rep"},{"issue":"3\u20134-5","key":"10.1016\/j.pcl.2024.01.018_bib19","first-page":"564","article-title":"A\u00a0field trial of Hong Kong-strain influenza vaccine in Seattle schoolchildren","volume":"41","author":"Foy","year":"1969","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.pcl.2024.01.018_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.1971.03190080029006","article-title":"Single-Dose Monovalent A2\/Hong Kong Influenza Vaccine: Efficacy 14 Months After Immunization","volume":"217","author":"Foy","year":"1971","journal-title":"JAMA"},{"issue":"3\u20134-5","key":"10.1016\/j.pcl.2024.01.018_bib21","first-page":"566","article-title":"A\u00a0field evaluation of inactivated, zonal-centrifuged influenza vaccines in children in Chapel Hill, North Carolina, 1968-69","volume":"41","author":"Glezen","year":"1969","journal-title":"Bull World Health Organ"},{"issue":"1\u20132","key":"10.1016\/j.pcl.2024.01.018_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/122.1-2.16","article-title":"Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren","volume":"122","author":"Monto","year":"1970","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.pcl.2024.01.018_bib23","first-page":"333","article-title":"Trials of aqueous killed influenza vaccine in Canada, 1968-69","volume":"49","author":"Williams","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib24","first-page":"151","article-title":"Field trial with human and equine influenza vaccines in children: protection and antibody titres","volume":"46","author":"Wesselius-de Casparis","year":"1972","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.pcl.2024.01.018_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/infdis\/134.6.633","article-title":"From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--II","volume":"134","author":"Wright","year":"1976","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.pcl.2024.01.018_bib26","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.pcl.2024.01.018_bib27","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.pcl.2024.01.018_bib29","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"8","key":"10.1016\/j.pcl.2024.01.018_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/INF.0000000000000329","article-title":"Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children","volume":"33","author":"Kotloff","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"9708","key":"10.1016\/j.pcl.2024.01.018_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.pcl.2024.01.018_bib32","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.pcl.2024.01.018_bib33","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.pcl.2024.01.018_bib34","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.pcl.2024.01.018_bib35","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7126e2","article-title":"Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022","volume":"71","author":"Fleming-Dutra","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cid\/ciaa1425","article-title":"Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?","volume":"73","author":"Anderson","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53590","article-title":"Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US","volume":"6","author":"Flaxman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcl.2024.01.018_bib38","unstructured":"Kuiken T, Gottron F. The Strategic National Stockpile: Overview and Issues for Congress."},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/jiab374","article-title":"M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain","volume":"226","author":"Eiden","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A\u00a0Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.pcl.2024.01.018_bib47","author":"CIVICs"},{"key":"10.1016\/j.pcl.2024.01.018_bib48","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.2686","article-title":"Reanalysis of the anthrax epidemic in Rhodesia, 1978\u20131984","volume":"4","author":"Wilson","year":"2016","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/08998280.2005.11928074","article-title":"Anthrax: a continuing concern in the era of bioterrorism","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.pcl.2024.01.018_bib50","unstructured":"Institute of Medicine (US) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine; Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL. Background. In: The Anthrax Vaccine: Is It Safe? Does It Work?. National Academies Press (US); 2002. Accessed December 7, 2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK220522\/."},{"issue":"8","key":"10.1016\/j.pcl.2024.01.018_bib51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(91)90237-Z","article-title":"Anthrax vaccines: past, present and future","volume":"9","author":"Turnbull","year":"1991","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3201\/eid1001.030238","article-title":"Bacillus anthracis Bioterrorism Incident, Kameido, Tokyo, 1993","volume":"10","author":"Takahashi","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.pcl.2024.01.018_bib54","article-title":"Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2000","volume":"49","author":"Centers for Disease Control and Prevention (CDC)","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"10.1016\/j.pcl.2024.01.018_bib55","first-page":"1024","article-title":"Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib58","doi-asserted-by":"crossref","first-page":"e130611","DOI":"10.3201\/eid2002.130611","article-title":"Special Considerations for Prophylaxis for and Treatment of Anthrax in Pregnant and Postpartum Women","volume":"20","author":"Meaney-Delman","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.pcl.2024.01.018_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","article-title":"Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019","volume":"68","author":"Bower","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.pcl.2024.01.018_bib62","author":"Emergent BioSolutions Receives U.S."},{"key":"10.1016\/j.pcl.2024.01.018_bib66","author":"Adewuni"},{"issue":"11","key":"10.1016\/j.pcl.2024.01.018_bib68","doi-asserted-by":"crossref","first-page":"e1743","DOI":"10.1016\/S2214-109X(23)00410-2","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone","volume":"11","author":"Choi","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"6","key":"10.1016\/j.pcl.2024.01.018_bib69","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.pcl.2024.01.018_bib70","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/v11080708","article-title":"Genome of Alaskapox Virus, a Novel Orthopoxvirus Isolated from Alaska","volume":"11","author":"Gigante","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.pcl.2024.01.018_bib71","series-title":"The 1971 Smallpox Epidemic in Aralsk, Kazakhstan and the Soviet Biological Warfare Program","year":"2002"},{"key":"10.1016\/j.pcl.2024.01.018_bib72","article-title":"NIH finds forgotten smallpox store","author":"Reardon","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pcl.2024.01.018_bib73","unstructured":"World Health Organization. Smallpox Eradication: Destruction of Variola Virus Stocks.; 2019."},{"issue":"10","key":"10.1016\/j.pcl.2024.01.018_bib74","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41558-021-01162-y","article-title":"Emergent biogeochemical risks from Arctic permafrost degradation","volume":"11","author":"Miner","year":"2021","journal-title":"Nat Clim Change"},{"issue":"4","key":"10.1016\/j.pcl.2024.01.018_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000\u2122: The new smallpox vaccine for United States Strategic National Stockpile","author":"Nalca","year":"2010","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.pcl.2024.01.018_bib78","first-page":"29","article-title":"Mpox in Children and Adolescents during Multicountry Outbreak, 2022-2023","author":"Hoxha","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.pcl.2024.01.018_bib82","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(23)00270-0","article-title":"Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara\u2013Bavaria Nordic vaccine against mpox in children: a national outbreak response","volume":"23","author":"Ladhani","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pcl.2024.01.018_bib85","unstructured":"NIAID Pandemic Preparedness Plan."},{"key":"10.1016\/j.pcl.2024.01.018_bib87","author":"NextGen"},{"issue":"3","key":"10.1016\/j.pcl.2024.01.018_bib90","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A\u00a0Novel Vaccine against Crimean-Congo Haemorrhagic Fever Protects 100% of Animals against Lethal Challenge in a Mouse Model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.pcl.2024.01.018_bib91","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","article-title":"A\u00a0Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease","volume":"12","author":"Dowall","year":"2015","journal-title":"Hum Vaccines Immunother"},{"issue":"10","key":"10.1016\/j.pcl.2024.01.018_bib92","doi-asserted-by":"crossref","first-page":"e1010805","DOI":"10.1371\/journal.ppat.1010805","article-title":"An introduction to the Marburg virus vaccine consortium","volume":"18","author":"Cross","year":"2022","journal-title":"MARVAC. PLOS Pathog."},{"issue":"7","key":"10.1016\/j.pcl.2024.01.018_bib93","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"9520","key":"10.1016\/j.pcl.2024.01.018_bib94","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"Daddario-DiCaprio","year":"2006","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib95","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"Supplement_7","key":"10.1016\/j.pcl.2024.01.018_bib96","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1093\/infdis\/jiad157","article-title":"A\u00a0Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus","volume":"228","author":"Woolsey","year":"2023","journal-title":"J\u00a0Infect Dis"},{"issue":"15","key":"10.1016\/j.pcl.2024.01.018_bib97","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcl.2024.01.018_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10373","key":"10.1016\/j.pcl.2024.01.018_bib99","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","article-title":"Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial","volume":"401","author":"Hamer","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.pcl.2024.01.018_bib100","author":"Guttman"},{"issue":"11","key":"10.1016\/j.pcl.2024.01.018_bib101","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395524000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395524000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T22:38:28Z","timestamp":1715726308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395524000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0031395524000294"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2024.01.018","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine Development","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}